Aptevo Therapeutics Inc. - Common Stock, par value $0.001 per share (APVO)
CUSIP: 03835L504
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 3,295,607
- Total 13F shares
- 493,997
- Share change
- +488,962
- Total reported value
- $717,121
- Price per share
- $1.45
- Number of holders
- 12
- Value change
- +$709,654
- Number of buys
- 9
- Number of sells
- 1
Quarterly Holders Quick Answers
What is CUSIP 03835L504?
CUSIP 03835L504 identifies APVO - Aptevo Therapeutics Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 03835L504:
Top shareholders of APVO - Aptevo Therapeutics Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| YA II PN, Ltd. |
13D/G
|
— |
10%
|
357,842
|
$1,663,965 | $0 | 16 Jun 2025 | |
| CVI Investments, Inc. |
13D/G
|
— |
9.9%
|
357,842
|
$1,073,526 | $0 | 30 Jun 2025 | |
| L1 Capital Global Opportunities Master Fund, Ltd. |
13D/G
|
— |
5%
|
164,300
|
$492,900 | -$362,100 | 14 Aug 2025 | |
| Ayrton Capital LLC |
13D/G
|
— |
10%
|
358,150
|
$107,445 | $0 | 30 Jun 2025 | |
| Hudson Bay Capital Management LP |
13D/G
|
— |
5%
|
76,598
|
$52,853 | $0 | 31 Dec 2024 | |
| Birchview Capital, LP |
13F
|
Company |
0.28%
|
10,000
|
$30,500 | — | 30 Jun 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.1%
|
3,250
|
$9,912 | — | 30 Jun 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.04%
|
1,192
|
$3,636 | — | 30 Jun 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.02%
|
588
|
$1,793 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
3
|
$9 | — | 30 Jun 2025 | |
| Marvin L. White |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
30,012
mixed-class rows
|
$3 | — | 06 Aug 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0%
|
1
|
$3 | — | 30 Jun 2025 | |
| DANSKE BANK A/S |
13F
|
Company |
0%
|
1
|
$3 | — | 30 Jun 2025 | |
| Jeffrey G. Lamothe |
3/4/5
|
EVP, COO |
—
mixed-class rows
|
17,306
mixed-class rows
|
$1 | — | 06 Aug 2025 | |
| SoYoung Kwon |
3/4/5
|
SVP, GC, BD & Corp Affairs |
—
mixed-class rows
|
11,504
mixed-class rows
|
$1 | — | 06 Aug 2025 | |
| BIGGER CAPITAL FUND L P |
13D/G
|
— |
10%
|
285,000
|
— | $0 | 18 Jun 2025 | |
| Fuad El-Hibri |
3/4/5
|
Director |
—
class O/S missing
|
87,697
|
— | — | 03 Dec 2021 | |
| Daphne Taylor |
3/4/5
|
SVP, CFO |
—
mixed-class rows
|
11,503
mixed-class rows
|
— | — | 06 Aug 2025 | |
| Dirk Huebner |
3/4/5
|
SVP, CMO |
—
class O/S missing
|
11,500
|
— | — | 06 Aug 2025 | |
| Barbara Lopez Kunz |
3/4/5
|
Director |
—
mixed-class rows
|
7,201
mixed-class rows
|
— | — | 06 Aug 2025 | |
| Daniel Abdun-Nabi |
3/4/5
|
Director |
—
mixed-class rows
|
7,201
mixed-class rows
|
— | — | 06 Aug 2025 | |
| John Niederhuber |
3/4/5
|
Director |
—
mixed-class rows
|
7,201
mixed-class rows
|
— | — | 06 Aug 2025 | |
| Zsolt Harsanyi |
3/4/5
|
Director |
—
mixed-class rows
|
7,201
mixed-class rows
|
— | — | 06 Aug 2025 |
Institutional Holders of Aptevo Therapeutics Inc. - Common Stock, par value $0.001 per share (APVO) as of Q3 2025
As of 30 Sep 2025,
Aptevo Therapeutics Inc. - Common Stock, par value $0.001 per share (APVO) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
493,997 shares.
The largest 10 holders included
Point72 Asset Management, L.P., DRW Securities, LLC, Virtu Financial LLC, Focus Partners Wealth, OSAIC HOLDINGS, INC., UBS Group AG, Tower Research Capital LLC (TRC), SBI Securities Co., Ltd., CITIGROUP INC, and BANK OF AMERICA CORP /DE/.
This page lists
12
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
6
Q3 2025 holders
12
Holder diff
6
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.